Kidney Disease

Calliditas Therapeutics' partner Everest Medicines' announces kidney drug approval

24-Nov-2023 By Liza Laws

Calliditas Therapeutics AB announced today (November 24) that its partner Everest Medicines has revealed that China's National Medical Products Administration (NMPA) has approved Nefecon.

Novartis 'excited' about top line results for chronic kidney disease treatment

02-Oct-2023 By Liza Laws

Novartis announced today (October 2) that it is excited about positive top-line results from its study into iptacopan, a drug to treat IgA nephropathy (IgAN).

Calliditas seeks full marketing authorization for drug to treat primary IgA nephropathy

28-Sep-2023 By Liza Laws

Calliditas Therapeutics says it is optimistic about getting full marketing authorization for a drug to treat primary IgA nephropathy (IgAN) after submitting a request to the European Medicines Agency (EMA).

FDA grants priority review for full approval of Calliditas' Tarpeyo to slow kidney decline

18-Aug-2023 By Liza Laws

A kidney disease drug with a ‘durable and clinically meaningful impact on kidney function’ has been granted priority review by the US Food and Drug Administration (FDA).

Calliditas Therapeutics advances kidney disease drug, meeting primary endpoint in study

15-Aug-2023 By Liza Laws

Calliditas Therapeutics AB’s phase 3 study looking at a cure for a kidney disease called IgA nephropathy (IgAN) has met its primary endpoint and the full data has been published in The Lancet.

CorMedix on track to put an end to infection misery for dialysis patients

08-Jun-2023 By Liza Laws

An antifungal and antimicrobial solution could put an end to the discomfort of infection that many patients with kidney disease often endure.

Relieving the itch - new treatment for CKD-associated pruritus in adults on haemodialysis

18-May-2023 By Liza Laws

A small molecule drug has been recommended by England’s National Institute for Health Care and Excellence (NICE) for the treatment of adults with moderate to severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis.

FDA gives priority review to Merck’s new drug application for kidney disease

20-Feb-2023 By Liza Laws

The US Food and Drug Administration (FDA) has accepted Merck’s Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in kidney transplant patients for priority review.

American Kidney Fund launches resources to engage patients of color

22-Aug-2022 By Jenni Spinner

The group has introduced a downloadable guide, interactive quiz, and other tools to inform patients from underrepresented communities about trial participation.

UK research hub launched to tackle rare kidney disease

31-Jan-2022 By Jenni Spinner

The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.

Insilico Medicine uses AI to uncover preclinical candidate for kidney fibrosis

23-Aug-2021 By Jenni Spinner

The drug discovery company reportedly used AI-powered drug discovery to come up with a promising preclinical candidate for treatment of the kidney ailment.